ArticleInternational journal of nanomedicine2019
Synergism of cisplatin-oleanolic acid co-loaded calcium carbonate nanoparticles on hepatocellular carcinoma cells for enhanced apoptosis and reduced hepatotoxicity.
Article in International journal of nanomedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 73 citations in OpenAlex.
- Ruxolitinib attenuates diethylnitrosamine-induced liver injury in mice: involvement of TLR4/MYD88/NF-κB and IL-6/JAK/STAT pathways.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Shikonin-Loaded Nanoparticles Attenuate Particulate Matter-Induced Skin Injury by Inhibiting Oxidative Stress and Inflammation.Antioxidants (Basel, Switzerland) · 2025Article
- The spatiotemporal heterogeneity of reactive oxygen species in the malignant transformation of viral hepatitis to hepatocellular carcinoma: a new insight.Cellular & molecular biology letters · 2025Review
- Exploring the therapeutic potential of oleanolic acid and its derivatives in cancer treatment: a comprehensive review.3 Biotech · 2025Review
- ModifiedWorld journal of gastroenterology · 2025Article
- Hepatocellular carcinoma: signaling pathways and therapeutic advances.Signal transduction and targeted therapy · 2025Review
- Molecular Targets and Nano-Technological Approaches in the Treatment of Hepatic Carcinoma.Current cancer drug targets · 2025Review
- Key Nano-Strategies for Cisplatin Resistance in Advancing Anti-Cancer Therapy.International journal of nanomedicine · 2025Review
- Nano-Formulations of Natural Antioxidants for the Treatment of Liver Cancer.Biomolecules · 2024Review
- Calcium Carbonate-Based Nanoplatforms for Cancer Therapeutics: Current State of Art and Future Breakthroughs.ACS omega · 2024Review
- Recent Developments in CaCOPharmaceutics · 2024Review
- Recent advances of novel targeted drug delivery systems based on natural medicine monomers against hepatocellular carcinoma.Heliyon · 2024Review
- Targeting the mTOR Pathway in Hepatocellular Carcinoma: The Therapeutic Potential of Natural Products.Journal of inflammation research · 2024Review
- Phytochemicals as Potential Lead Molecules against Hepatocellular Carcinoma.Current medicinal chemistry · 2024Review
- Cisplatin-Based Combination Therapy for Enhanced Cancer Treatment.Current drug targets · 2024Review
- Bionic natural small molecule co-assemblies towards targeted and synergistic Chemo/PDT/CDT.Biomaterials research · 2023Article
- Codelivery of Phytochemicals with Conventional Anticancer Drugs in Form of Nanocarriers.Pharmaceutics · 2023Review
- The improving strategies and applications of nanotechnology-based drugs in hepatocellular carcinoma treatment.Frontiers in bioengineering and biotechnology · 2023Review
- Nano-drug co-delivery system of natural active ingredients and chemotherapy drugs for cancer treatment: a review.Drug delivery · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.